Brought to you by 
BI, Vectura develop inhaler for respiratory diseases; ends
17 Dec 2009
Executive Summary
Boehringer Ingelheim will work with Vectura Group (inhaled compounds and device technologies for lung diseases) to develop a branded dry powder inhaler (DPI) delivering BI's compounds primarily as asthma and chronic obstructive pulmonary disease (COPD) treatments. BI makes a 3.8% equity investment in Vectura.
Deal Industry
- Biotechnology
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BI, Vectura develop inhaler for respiratory diseases; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice